The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|May 2, 2013
- Pharmaceutical Technology-05-02-2013
- Volume 37
- Issue 5
Pharmaceutical Technology, May 2013 Issue (PDF)
Click the title above to open the Pharmaceutical Technology May 2013 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 13 years ago
ZFN Technology Advances Biopharmaceutical Manufacturingover 13 years ago
Compositing Samples and the Risk to Product Qualityover 13 years ago
Regulatory Convergence Sought for Global Pharma Marketover 13 years ago
FDA Expectations for Supplier Managementover 13 years ago
Intellectual Property Battles in Solid-State Chemistryover 13 years ago
Prefilled Syringes or Peptide Pills?over 13 years ago
Academic and Public Partnerships in Solid-State Chemistryover 13 years ago
Q&A with Stuart E. Needleman, Aptuitover 13 years ago
New First-to-File Patent Rule Threatens Open CollaborationAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5